Application of Human Liver Microsomes in Metabolism-Based Drug-Drug Interactions: In Vitro-in Vivo Correlations and the Abbott Laboratories Experience

Advances in Pharmacology

Volumn 43, Issue C, 1997, Pages 65-101

  Rodrigues, A David ^a   Wong, Shekman L ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450; DESIPRAMINE; DRUG; ISOENZYME; RITONAVIR; TERFENADINE;

ANIMAL; DRUG ANTAGONISM; DRUG INTERACTION; DRUG SCREENING; HUMAN; LIVER MICROSOME; METABOLISM; METHODOLOGY; REVIEW;

ANIMALS; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; DESIPRAMINE; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; RITONAVIR; TERFENADINE;

EID: 0030631259     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60202-1     Document Type: Article

References (120)

1. Albengres E., and Tillement J.P. Cyclosporin and ketoconazole, drug interaction or therapeutic association. Int. J. Clin. Pharmacol. Ther. Toxicol. 30 (1992) 555-570
2. Amsden G.W. Macrolides versus azalides: A drug interaction update. Ann. Pharmacother. 29 (1995) 906-917
3. Back D.J., and Tjia J.F. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br. J. Clin. Pharmacol. 32 (1991) 624-626
4. Ball S.E., Scatina J.A., Sisenwine S.F., and Fisher G.L. The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development. Drug Chem. Toxicol. 18 (1995) 1-28
5. Batt A.M., Magdalou J., Vincent-Viry M., Ouzzine M., Fournel-Gigleux S., Galteua M.M., and Siest G. Drug metabolizing enzymes related to laboratory medicine: Cytochromes P450 and UDP-glucuronosyltransferases. Clin. Chim. Acta 226 (1994) 171-190
6. Bergstrom R.F., Peyton A.L., and Lemberger L. Quantification and mechanism of fluoxetine and tricyclic antidepressant interaction. Clin. Pharmacol. Ther. 51 (1992) 239-248
7. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin. Pharmacokinet. 29 (1995) 192-209
8. Bloomer J.C., Clarke S.E., and Chenery R.J. Determination of P4501A2 activity in human liver microsomes using [3-14C-methyl]caffeine. Xenobiotica 25 (1995) 917-927
9. Bock K.W. Human UDP-glucuronosyltransferases: Classification and properties of isozymes. In: Pacifici G.M., and Fracchia G.N. (Eds). "Advances in Drug Metabolism in Man" (1995), European Commission, Brussels, Belgium 291-309
10. Boobis A.R. Predicting of inhibitory drug-drug interactions by studies in vitro. In: Pacifici G.M., and Fracchia G.N. (Eds). "Advances in Drug Metabolism in Man" (1995), European Commission, Brussels, Belgium 515-539
11. Braeckman R.A., Granneman G.R., Rubin P.R., and Kesterson J.W. Pharmacokinetics and metabolism of the new 5-lipoxygenase inhibitor A-64077 after a single oral administration in man (abstr.). J. Clin. Pharmacol. 29 (1989) A22
12. Breimer D.D. Genetic polymorphisms in drug metabolism: Clinical implications and consequences in ADME studies. In: Walker S., Lumley C., and McAuslane N. (Eds). "The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines" (1994), Kluwer Academic, Boston 13-26
13. Broly F., Libersa C., Lhermitte M., Bechtel P., and Dupuis B. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br. J. Clin. Pharmacol. 28 (1989) 29-36
14. Bronson D.D., Daniels D.M., Dixon J.T., Redick C.C., and Haaland P.D. Virtual kinetics: Using statistical experimental design for rapid analysis of enzyme inhibitor mechanisms. Biochem. Pharmacol. 50 (1995) 823-831
15. Brosen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin. Invest. 71 (1993) 1002-1009
16. Brosen K., and Gram L.F. First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther. 43 (1988) 400-406
17. Brosen K., and Gram L.F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol. 36 (1989) 537-547
18. Brosen K., and Gram L.F. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur. J. Clin. Pharmacol. 37 (1989) 155-160
19. Brosen K., Otton S.V., and Gram L.F. Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther. 40 (1986) 543-549
20. Brosen K., Hansen J.G., Nielsen K.K., Sindrup S.H., and Gram L.F. Inhibition by paroxetine of desipramine metabolism in extensive but not poor metabolizers of sparteine. Eur. J. Clin. Pharmacol. 44 (1993) 349-355
21. Burchell B., Nebert D.W., Nelson D.R., Bock K.W., Iyanagi T., Jansen P.L.M., Lancet D., Mulder G.J., Chowdhury J.R., Siest G., Tephly T.R., and Mackenzie P.I. The UDP-giucuronosyltransferase gene superfamily: Suggested nomenclature based on evolutionary divergence. DNA Cell Biol. 10 (1991) 487-494
22. Burchell B., Brierley C.H., and Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci. 57 (1995) 1819-1831
23. Coundouris J.A., Grant M.H., Engeset J., Petrie J.C., and Hawksworth G.M. Cryopreservation of human adult hepatocytes for use in drug metabolism and toxicity. Xenobiotica 23 (1993) 1399-1409
24. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., and Haddock R.E. The effect of paroxetine and other specific 5-HT re-uptake inhibitors on cytochrome P450IID6 activity in human liver microsomes. Br. J. Clin. Pharmacol. 32 (1991) 658
25. Danner S.A., Carr A., Leonard J.M., Lehman L.M., Gudiol F., Gonzalez J., Raventos A., Rubio R., Bouza E., Pintado V., Aguado A.G., Garcia De Lomas J., Delgado R., Borleffs J.C.C., Hsu A., Valdes J.M., Boucher C.A.B., and Cooper D.A. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333 (1995) 1528-1533
26. DeVane C.L. Pharmacogenetics and drug metabolism of newer antidepressant agents. J. Clin. Psychiatry 55 (1994) 38-45
27. Eberts F.S., Philopoulos Y., Reineke L.M., and Vliek R.W. Triazolam disposition. Clin. Pharmacol. Ther. 29 (1981) 81-93
28. Eichler J., Appel J.R., Blondelle S.E., Dooley C.T., Dorner B., Ostresh J.M., Perez-Paya E., Pinilla C., and Houghten R.A. Peptide, peptidomimetic, and organic synthetic combinatorial libraries. Med. Res. Rev. 15 (1995) 481-496
29. Erb R.J. The backpropagation neural network-a Bayesian classifier. Clin. Pharmacokinet 29 (1995) 69-79
30. Fabre G., Rahmani R., Placidi M., Combalbert J., Covo J., Cano J.-P., Coulange C., Ducros M., and Rampal M. Characterization of midazolam metabolism using human microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem. Pharmacol. 37 (1988) 4389-4397
31. Farrar G., Mitchell A.M., Hooper H., Stewart F., and Malcolm S.L. Prediction of potential drug interactions of saquinavir (Ro 31-8959) from in vitro data (abstr.). Br. J. Clin. Pharmacol. 38 (1994) 162
32. Ferrero J.L., Bopp B.A., Marsh K.C., Quigley S.C., Johnson M.J., Anderson D.J., Lamm J.E., Tolman K.G., Sanders S.W., Cavanaugh J.H., and Sonders R.C. Metabolism and disposition of clarithromycin in man. Drug Metab. Dispos. 18 (1990) 441-446
33. Garteiz D.A., Hook R.H., Walker B.J., and Okerholm R.A. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim.-Forsch. 32 (1982) 1185-1190
34. de Goldstein J.A., and Morais S.M.F. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4 (1994) 285-299
35. Gonzalez F.J., and Idle J.R. Pharmacogenetic phenotyping and genotyping: Present status and future potential. Clin. Pharmacokinet. 26 (1994) 59-70
36. Gorski J.C., Hall S.D., Jones D.R., VandenBranden M., and Wrighton S.A. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47 (1994) 1643-1653
37. Granneman G.R., Braeckman R.A., Locke C.S., Cavanaugh J.H., Dube L.M., and Awni W.M. Effect of zileuton on theophylline pharmacokinetics. Clin. Pharmacokinet. 29 Suppl. 2 (1995) 77-83
38. Grimsley S.R., and Jann M.W. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors. Clin. Pharm. 11 (1992) 930-957
39. Guengerich F.P. Characterization of human cytochrome P450 enzymes. FASEB J. 6 (1992) 745-748
40. Guengerich F.P. Cytochromes P450 of human liver. Classification and activity profiles of the major enzymes. In: Pacifici G.M., and Fracchia G.N. (Eds). "Advances in Drug Metabolism in Man" (1995), European Commission, Brussels, Belgium 181-231
41. Guengerich F.P., Muller-Enoch D., and Blair I.A. Oxidation of quinidine by human liver cytochrome P450. Mol. Pharmacol. 30 (1986) 287-295
42. Harris S., Hilligoss D.M., Colangelo P.M., Eller M., and Okerholm R. Azithromycin and terfenadine: Lack of drug interaction. Clin. Pharmacol. Ther. 58 (1995) 310-315
43. Hayes R.N., Pool W.F., Sinz M.W., and Woolf T.F. Recent developments in drug metabolism methodology. In: Welling P.G., and Tse F.L.S. (Eds). "Pharmacokinetics: Regulatory, Industrial, Academic Perspectives" (1995), Dekker, New York 201-234
44. Heizmann P., and Ziegler W.H. Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneim. -Forsch. 31 (1981) 2220-2223
45. Hensleigh M., Chiba M., and Lin J.H. Hepatic and intestinal metabolism of MK-639, an HIV protease inhibitor, in rats and human. Pharm. Res. 12 (1995) S374
46. Honig P.K., Wortham D.C., Zamani K., Mullin J.C., Conner D.P., and Cantilena L.R. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther. 53 (1993) 630-636
47. Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., and Cantilena L.R. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA, J. Am. Med. Assoc. 269 (1993) 1513-1518
48. Honig P.K., Wortham D.C., Zamani K., and Cantilena L.R. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest. 7 (1994) 148-156
49. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47 (1994) 1469-1479
50. Hukkinen S.K., Varhe A., Olkkola K.T., and Neuvonen P.J. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin. Pharmacol. Ther. 58 (1995) 127-131
51. Kaye C.M., Haddock R.E., Langley P.F., Mellows G., Tasker T.C.G., Zussaman B.D., and Greb W.H. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr. Scand. 80 (1989) 60-75
52. Kempf D.J. Progress in the discovery of orally bioavailable inhibitors of HIV protease. Perspect. Drug Discovery Des. 2 (1994) 427-436
53. Kempf D.J., Marsh K.C., Denissen J.F., McDonald E., Vasavanonda S., Flentge C.A., Green B.E., Fino L., Park C.H., Kong X.-P., Wideburg N.E., Saldivar A., Ruiz L., Kati W.M., Sham H.L., Robins T., Stewart K.D., Hsu A., Plattner J.J., Leonard J.M., and Norbeck D.W. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 2484-2488
54. Kempf D.J., Kumar G., Rodrigues A.D., Denissen J.F., Marsh K.C., Kukulka M.J., McDonald E., Norbeck D.W., and Leonard J.M. Pharmacokinetic enhancement of HIV protease inhibitors by coadministration with ritonavir. Antimicrob. Agents Chemother. 41 (1997) 654-660
55. Keogh A., Spratt P., McCosker C., MacDonald P., Mundy J., and Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N. Engl. J. Med. 333 (1995) 628-633
56. Ketter T.A., Flockhart D.A., Post R.M., Denicoff K., Pazzaglia P.J., Marangell L.B., George M.S., and Callahan A.M. The emerging role of cytochrome P450 3A in psychopharmacology. J. Clin. Psychopharmacol. 15 (1995) 387-398
57. Kubinyi H. Strategies and recent technologies in drug discovery. Pharmazie 50 (1995) 647-662
58. Kumar G.N., Rodrigues A.D., Buko A.M., and Denissen J.F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ABT-538 in human liver microsomes. J. Pharmacol. Exp. Ther. 277 (1996) 423-431
59. Kupferschmidt H.H.T., Ha H.R., Ziegler W.H., Meier P.J., and Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 58 (1995) 20-28
60. Lawton M.P., Cashman J.R., Cresteil T., Dolphin C.T., Elfarra A.A., Hines R.N., Hodgson E., Kimura T., Ozols J., Phillips I.R., Philpot R.M., Poulsen L.L., Rettie A.E., Shepard E.A., Williams D.E., and Ziegler D.M. A nomenclature for the mammalian flavin-containing monoxygenase gene family based on amino acid sequence identities. Arch. Biochem. Biophys. 308 (1994) 254-257
61. Lee H.S., Jin C.B., Chong H.S., Yun C.H., Park J.S., and Kim D.H. Involvement of P4503A in the metabolism of 7, 8-benzoflavone by human liver microsomes. Xenobiotica 24 (1994) 1053-1062
62. Leeman T.D., and Dayer P. Quantitative prediction of in vivo drug metabolism and interactions from in vitro data. In: Pacifici G.M., and Fracchia G.N. (Eds). "Advances in Drug Metabolism in Man" (1995), European Commission, Brussels, Belgium 785-830
63. Lewis D.F.V., and Lake B.G. Molecular modeling of members of the P4502A subfamily: Application to studies of enzyme specificity. Xenobiotica 25 (1995) 585-598
64. Machinist J.M., Mayer M.D., Shet M.S., Ferrero J.L., and Rodrigues A.D. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab. Dispos. 23 (1995) 1163-1174
65. Mancy A., Broto P., Dijols S., Dansette P.M., and Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: An approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 34 (1995) 10365-10375
66. Meltzer H.Y. Paroxetine: A safe and effective once-daily oral antidepressant agent. Hosp. Formul. 28 (1993) 4-13
67. Meyer F.P. Indicative therapeutic and toxic drug concentrations in plasma: A tabulation. Int. J. Clin. Pharmacol. Ther. 32 (1994) 71-81
68. Miners J.O., Veronese M.E., and Birkett D.J. In vitro approaches for the prediction of human drug metabolism. Annu. Rep. Med. Chem. 29 (1994) 307-316
69. Nelson D.R., Kamataki T., Waxman D.J., Guengerich F.P., Estabrook R.W., Feyereisen R., Gonzalez F.J., Coon M.J., Gunsalus I.C., Gotoh O., Okuda K., and Nebert D.W. The P450 superfamily: Update of new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12 (1993) 1-51
70. Olkkola K.T., Backman J.T., and Neuvonen P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole and itraconazole. Clin. Pharmacol. Ther. 55 (1994) 481-485
71. Otton S.V., Wu D., Joffe R.T., Cheung S.W., and Sellers E.M. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Ther. 53 (1993) 401-409
72. Peck C.C., Temple R., and Collins J.M. Understanding consequences of concurrent therapies. JAMA, J. Am. Med. Assoc. 269 (1993) 1550-1552
73. Pichard L., Fabre I., Fabre G., Domergue J., Saint Aubert B., Mourad G., and Maurel P. Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18 (1990) 595-606
74. Preskorn S.H., Alderman J., Chung M., Harrison W., Messig M., and Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J. Clin Psychopharmacol. 14 (1994) 90-98
75. Rifkind A.B., Lee C., Chang T.K.H., and Waxman D.J. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: Regioselective oxygenation and evidence for a role for CYP2C enzymes in aracidonic acid epoxygenation in human liver microsomes. Arch. Biochem. Biophys. 320 (1995) 380-389
76. Rodrigues A.D. Use of in vitro human metabolism studies in drug development: An industrial perspective. Biochem. Pharmacol. 48 (1994) 2147-2156
77. Rodrigues A.D., and Freston J.W. Do PPI effects on the cytochrome P450 system have implications to significant drug interactions?. In: Giuli R., Tytgat G.N.J., DeMeester T.R., and Galmiche J.P. (Eds). "The Esophageal Musoca: 300 Questions-300 Answers" (1994), Elsevier, New York 460-464
78. Rodrigues A.D., Lewis D.F.V., Ioannides C., and Parke D.V. Spectral and kinetic studies of the interaction of imidazole antifungal agents with microsomal cytochromes P450. Xenobiotica 17 (1987) 1315-1327
79. Rodrigues A.D., Kukulka M.J., Surber B.W., Thomas S.B., Uchic J.T., Rotert G.A., Michel G., Thome-Kromer B., and Machinist J.M. Measurement of liver microsomal cytochrome P450 (CYP2D6) activity using [O-methyl14C]dextromethorphan. Anal. Biochem. 219 (1994) 309-320
80. Rodrigues A.D., Mulford D.J., Lee R.D., Surber B.W., Kukulka M.J., Ferrero J.L., Thomas S.B., Shet M.S., and Estabrook R.W. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase: Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab. Dispos. 23 (1995) 765-775
81. Rodrigues A.D., Kukulka M.J., Ferrero J.L., and Cashman J.R. In vitro hepatic metabolism of ABT-418 in chimpanzee (pan troglodytes): A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N′-oxidation. Drug Metab. Dispos. 23 (1995) 1143-1152
82. Rodrigues A.D., Kukulka M.J., Roberts E.M., Ouellet D., and Rodgers T.R. [O-Methyl14C]naproxen O-demethylase activity in human liver microsomes: Evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab. Dispos. 24 (1996) 126-136
83. Rowland M., and Matin S.B. Kinetics of drug-drug interactions. J. Pharmacokinet. Biopharm. 1 (1973) 553-567
84. Rowland M., Matin S.B., Thiessen J., and Karam J. Kinetics of tolbutamide interactions. In: Morselli P.L., Garattini S., and Cohen S.N. (Eds). "Drug Interactions" (1974), Raven Press, New York 199-210
85. Roy A.K., Birkmeier J., Mirkin E., Volpe N., Yuan J., Stolzenbach J., and Schoenhard G. Metabolism of the HIV protease inhibitor SC-52151 in human liver microsomes in vitro: Involvement of cytochrome P450 3A (abstr.). Pharm. Res. 12 (1995) S375
86. Schentag J.J. Assessment of pharmacokinetic drug interactions in clinical drug development. In: Yacobi A., Skelly J.P., Shah V.P., and Benet L.Z. (Eds). "Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development" (1993), Plenum, New York 149-157
87. Segel I.H. "Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems," (1993), Wiley, New York 100-226
88. Sharer J.E., Shipley L.A., Vandenbranden M.R., Binkley S.N., and Wrighton S.A. Comparisons of Phase I and Phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab. Dispos. 23 (1995) 1231-1241
89. Smith D.A. Species differences in metabolism and pharmacokinetics: Are we close to an understanding. Drug Metab. Rev. 23 (1991) 355-373
90. Smith D.A., and Jones B.C. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol. 44 (1992) 2089-2098
91. Smith L.R., and Wilkinson C.F. Influence of steric factors on the interaction of isomeric phenyloxazoles and phenylthiazoles with microsomal oxidation. Biochem. Pharmacol. 27 (1978) 2466-2467
92. Somogyi A., and Muirhead M. Pharmacokinetic interactions with cimetidine. Clin. Pharmacokinet. 12 (1987) 321-366
93. Spina E., Birgersson C., von Bahr C., Ericsson O., Mellstromöm B., Steiner E., and Sjöqvist F. Phenotypic consistency in hydroxylation of desmethyl-imipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin. Pharmacol. Ther. 36 (1984) 677-682
94. Spina E., Pollicino A.M., Avenoso A., Campo G.M., Perucca E., and Caputi A.P. Effect of fluoxetine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther. Drug Monit. 15 (1993) 243-246
95. Steiner E., Dumont E., Spina E., and Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin. Pharmacol. Ther. 43 (1987) 577-581
96. Steinijans V.W., Huber R., Hartmann M., Zech K., Bliesath H., Wurst W., and Radtke H.W. Lack of pantoprazole drug interactions in man. Int. J. Clin. Pharmacol. Ther. 32 (1994) 386-399
97. Peter J.V., Braeckman St.R.A., Granneman G.R., Locke C.S., Cavanaugh J.H., Awni W.M., and Dube L. The effect of zileuton on antipyrine and indocynanine green disposition. Clin. Pharmacol. Ther. 57 (1995) 299-308
98. Strobl G.R., von Kruedener S., Stockigt J., Guengerich F.P., and Wolff T. Development of a pharmacophore for inhibition of human liver cytochrome P450 2D6: Molecular modeling and inhibition studies. J. Med. Chem. 36 (1993) 1136-1145
99. Sueyoshi T., Park L.J., Moore R., Juvonen R.O., and Negishi M. Molecular engineering of microsomal P450 2a-4 to a stable, water-soluble enzyme. Arch. Biochem. Biophys. 322 (1995) 265-271
100. Temple R. Trends in pharmaceutical development. Drug Inf. J. 27 (1993) 355-366
101. Tucker G.T. The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. Int. J. Clin. Pharmacol. Ther. Toxicol. 30 (1992) 550-553
102. Tucker G.T. Clinical implications of genetic polymorphism in drug metabolism. J. Pharm. Pharmacol. 46 (1994) 417-424
103. Vanakoski J., Mattila M.J., Vainio P., Idanpaan-Heikkila J.J., and Tornwall M. 150 mg Fluconazole does not substantially increase the effects of 10 mg midazolam or plasma midazolam concentrations in healthy subjects. Int. J. Clin. Pharmacol. Ther. 33 (1995) 518-523
104. Van Harten J. Clinical pharmacokinetics sertonin reuptake inhibitors. Clin. Pharmacokinet. 24 (1993) 203-220
105. Varhe A., Olkkola K.T., and Neuvonen P.J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole for itraconazole. Clin. Pharmacol. Ther. 56 (1994) 601-607
106. Vatsis K.P., Weber W.W., Bell D.A., Dupret J.M., Price Evans E.A., Grant D.M., Hein D.W., Lin H.J., Meyer U.A., Relling M.V., Sim E., Suzuki T., and Yamazoe Y. Nomenclature for N-acetyltransferases. Pharmacogenetics 5 (1995) 1-17
107. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Harmatz J.S., and Shader R.I. Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br. J. Clin. Pharmacol. 38 (1994) 23-31
108. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Duan S.X., Harmatz J.S., and Shader R.I. Inhibition of desipramine metabolism in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J. Pharmacol. Exp. Ther. 268 (1994) 1278-1283
109. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Duan S.X., Harmatz J.S., and Shader R.I. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharmacol. 34 (1994) 1222-1227
110. von Moltke L.L., Greenblatt D.J., Court M.H., Duan S.X., Harmatz J.S., and Shader R.I. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin-reuptake-inhibitor antidepressants. J. Clin. Psychopharmacol. 15 (1995) 125-131
111. von Moltke L.L., Greenblatt D.J., Schmider J., Harmatz J.S., and Shader R.I. Metabolism of drugs by cytochrome P450 3A isoforms: Implications for drug interactions in psychopharmacology. Clin. Pharmacokinet. 29 Suppl. 1 (1995) 33-44
112. Vree T.B., Van Den Biggelaar-Matea M., Verwey-Van Wissen C.P., Vree W.G.M.M.K., and Guelen P.J.M. The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. Br. J. Clin. Pharmacol. 35 (1993) 467-472
113. Walle T., Walle U.K., and Olanoff L.S. Quantitative account of propranolol metabolism in urine of normal man. Drug Metab. Dipos. 13 (1985) 204-209
114. Webb J.L. The kinetics of enzyme inhibition. "Enzyme and Metabolic Inhibitors," Vol. 1 (1963), Academic Press, London 49-65
115. Wilde M.L., and Balfour J.A. Gestodene: A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs 50 (1995) 364-395
116. Wilkinson G.R. Clearance approaches in pharmacology. Pharmacol. Rev. 39 (1987) 1-47
117. Wrighton S.A., and Ring B.J. Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm. Res. 11 (1994) 921-928
118. Wrighton S.A., and Stevens J.C. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22 (1992) 1-21
119. Wrighton S.A., VandenBranden M., Stevens J.C., Shipley L.A., and Ring B.J. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25 (1993) 453-484
120. Zeldin D.C., Dubois R.N., Falck J.R., and Capdevila J.H. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch. Biochem. Biophys. 322 (1995) 76-86